Literature DB >> 21184632

Petroclival meningiomas: study on outcomes, complications and recurrence rates.

Anil Nanda1, Vijayakumar Javalkar, Anirban Deep Banerjee.   

Abstract

OBJECT: Petroclival meningiomas are notoriously difficult lesions to manage surgically, given the critical neurovascular structures that are intimately associated with the tumors. In this paper, the authors' aim was to review their series of patients with petroclival meningiomas who underwent surgical treatment; emphasis was placed on evaluating modes of presentation, postoperative neurological outcome, complications, and recurrence rates.
METHODS: Fifty patients underwent surgical treatment for petroclival meningiomas. The majority of the patients were women (72%). The authors retrospectively reviewed the patients' medical records, imaging studies, and pathology reports to analyze presentation, surgical approach, neurological outcomes, complications, and recurrence rates.
RESULTS: Headache was the most common presentation (58%). The most commonly used approach was the transpetrous approach (in 16 patients), followed by the orbitozygomatic approach (in 13). Gross-total resection was performed in 14 patients (28%), and in the remaining patients there was residual tumor (72%). Eighteen patients with tumor remnants were treated with Gamma Knife surgery. New postoperative cranial neuropathies were noted in 22 patients (44%). The most common cranial nerve (CN) deficit following surgery was CN III dysfunction (in 11 patients) and facial weakness (in 10). In 9 patients, the CN dysfunction was transient (41%), and 7 patients had permanent dysfunction (32%). Eight patients developed hydrocephalus and all required placement of a ventriculoperitoneal shunt. A CSF leak was noted in only 2 patients (4%), and wound dehiscence was noted in 1. The CSF leaks and the wound dehiscence occurred in patients who were undergoing reoperations. Adequate radiographic follow-up (minimum 6 months) was available for 31 patients (62%). The mean follow-up was 22.1 months. In 6 patients, tumor progression or recurrences were noted. The median time to recurrence was 84 months. At the time of discharge from the hospital, 92% of the patients had good outcomes (Glasgow Outcome Scale Scores 4 and 5). Three patients died of causes not directly related to the surgery.
CONCLUSIONS: Petroclival meningiomas still pose a formidable challenge to neurosurgeons. In their series, the authors used multiple skull base approaches and careful microneurosurgical technique to achieve a good functional outcome (Glasgow Outcome Scale Score 4 or 5) in 92% of patients, although the extent of gross-total resection was only 28%. The authors' primary surgical goal was to achieve maximal tumor resection while maintaining or improving neurological function. The authors favor the treatment of residual tumor or recurrent tumor with stereotactic radiosurgery.

Entities:  

Mesh:

Year:  2010        PMID: 21184632     DOI: 10.3171/2010.11.JNS10326

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  38 in total

1.  Meningiomas: skull base versus non-skull base.

Authors:  Torstein R Meling; Michele Da Broi; David Scheie; Eirik Helseth
Journal:  Neurosurg Rev       Date:  2018-04-07       Impact factor: 3.042

2.  Hypofractionated stereotactic radiation therapy in skull base meningiomas.

Authors:  Pierina Navarria; Federico Pessina; Luca Cozzi; Elena Clerici; Elisa Villa; Anna Maria Ascolese; Fiorenza De Rose; Tiziana Comito; Ciro Franzese; Giuseppe D'Agostino; Francesca Lobefalo; Antonella Fogliata; Giacomo Reggiori; Maurizio Fornari; Stefano Tomatis; Lorenzo Bello; Marta Scorsetti
Journal:  J Neurooncol       Date:  2015-06-04       Impact factor: 4.130

3.  Risk of Developing Postoperative Deficits Based on Tumor Location after Surgical Resection of an Intracranial Meningioma.

Authors:  Jeff S Ehresman; Tomas Garzon-Muvdi; Davis Rogers; Michael Lim; Gary L Gallia; Jon Weingart; Henry Brem; Chetan Bettegowda; Kaisorn L Chaichana
Journal:  J Neurol Surg B Skull Base       Date:  2018-07-17

4.  Radiosurgery vs. microsurgery for newly diagnosed, small petroclival meningiomas with trigeminal neuralgia.

Authors:  Hun Ho Park; Woo Hyun Kim; Hyun-Ho Jung; Jong Hee Chang; Kyu-Sung Lee; Won Seok Chang; Chang-Ki Hong
Journal:  Neurosurg Rev       Date:  2020-07-08       Impact factor: 3.042

5.  Facial nerve function after the extended translabyrinthine approach.

Authors:  Mia E Miller; Bill Mastrodimos; Roberto A Cueva
Journal:  J Neurol Surg B Skull Base       Date:  2014-08-11

6.  A comparison of clinicopathological features and surgical outcomes between pediatric skull base and non-skull base meningiomas.

Authors:  Zhicen Li; Hao Li; Yuming Jiao; Ji Ma; Shuo Wang; Jizong Zhao; Yong Cao
Journal:  Childs Nerv Syst       Date:  2016-10-29       Impact factor: 1.475

7.  Partial skull base tumour resection in combination with radiosurgery: an escape procedure or a reasonable solution of treatment?

Authors:  Gorazd Bunc; Janez Ravnik; Maja Ravnik; Tomaz Velnar
Journal:  Wien Klin Wochenschr       Date:  2015-04-30       Impact factor: 1.704

8.  Value of K i -67 Labeling Index in Predicting Recurrence of WHO Grade I Cranial Base Meningiomas.

Authors:  Jose Gabrielle Matias; Ignacio Jusue-Torres; Brendan Martin; Ankush Bajaj; Ewa Borys; Edward Melian; Kevin Barton; Douglas E Anderson; Vikram C Prabhu
Journal:  J Neurol Surg B Skull Base       Date:  2018-09-06

9.  Quantitative comparison of retrosigmoid intradural suprameatal approach and retrosigmoid transtentorial approach: implications for tumors in the petroclival region.

Authors:  Sudheer Ambekar; Chiazo Amene; Ashish Sonig; Bharat Guthikonda; Anil Nanda
Journal:  J Neurol Surg B Skull Base       Date:  2013-06-13

10.  Recurrent petroclival meningiomas: clinical characteristics, management, and outcomes.

Authors:  Da Li; Shu-Yu Hao; Liang Wang; Jie Tang; Xin-Ru Xiao; Gui-Jun Jia; Zhen Wu; Li-Wei Zhang; Jun-Ting Zhang
Journal:  Neurosurg Rev       Date:  2014-10-16       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.